235 related articles for article (PubMed ID: 21144599)
1. Treating inflammation with the Janus kinase inhibitor CP-690,550.
Vijayakrishnan L; Venkataramanan R; Gulati P
Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
[TBL] [Abstract][Full Text] [Related]
2. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
West K
Curr Opin Investig Drugs; 2009 May; 10(5):491-504. PubMed ID: 19431082
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib in kidney transplantation.
Wojciechowski D; Vincenti F
Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
[TBL] [Abstract][Full Text] [Related]
4. Targeting JAK3 in kidney transplantation: current status and future options.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2011 Dec; 16(6):614-9. PubMed ID: 21971513
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
[TBL] [Abstract][Full Text] [Related]
6. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.
Kudlacz E; Conklyn M; Andresen C; Whitney-Pickett C; Changelian P
Eur J Pharmacol; 2008 Mar; 582(1-3):154-61. PubMed ID: 18242596
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
9. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545.
Deuse T; Hua X; Taylor V; Stubbendorff M; Baluom M; Chen Y; Park G; Velden J; Streichert T; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2012 Oct; 94(7):695-702. PubMed ID: 22971540
[TBL] [Abstract][Full Text] [Related]
10. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Borie DC; O'Shea JJ; Changelian PS
Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
[TBL] [Abstract][Full Text] [Related]
11. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Flanagan ME; Blumenkopf TA; Brissette WH; Brown MF; Casavant JM; Shang-Poa C; Doty JL; Elliott EA; Fisher MB; Hines M; Kent C; Kudlacz EM; Lillie BM; Magnuson KS; McCurdy SP; Munchhof MJ; Perry BD; Sawyer PS; Strelevitz TJ; Subramanyam C; Sun J; Whipple DA; Changelian PS
J Med Chem; 2010 Dec; 53(24):8468-84. PubMed ID: 21105711
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase 3: a novel target for selective transplant immunosupression.
Podder H; Kahan BD
Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
16. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
[TBL] [Abstract][Full Text] [Related]
17. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
18. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
Norman P
Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
Borie DC; Changelian PS; Larson MJ; Si MS; Paniagua R; Higgins JP; Holm B; Campbell A; Lau M; Zhang S; Flores MG; Rousvoal G; Hawkins J; Ball DA; Kudlacz EM; Brissette WH; Elliott EA; Reitz BA; Morris RE
Transplantation; 2005 Apr; 79(7):791-801. PubMed ID: 15818321
[TBL] [Abstract][Full Text] [Related]
20. Targeting JAK/STAT Signaling to Prevent Rejection After Kidney Transplantation: A Reappraisal.
Baan CC; Kannegieter NM; Felipe CR; Tedesco Silva H
Transplantation; 2016 Sep; 100(9):1833-9. PubMed ID: 27163538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]